April 2025 Br J Cardiol 2025;32:77–80 doi:10.5837/bjc.2025.017
Ketut Angga Aditya Putra Pramana, Ni Gusti Ayu Made Sintya Dwi Cahyani, Yusra Pintaningrum
Introduction According to projections, coronary artery disease (CAD), which is brought on by the atherosclerotic process in coronary arteries, will continue to be the world’s leading cause of death and morbidity.1,2 The development of coronary lesions may increase the risk of mortality for patients by causing serious adverse cardiovascular events including acute coronary syndrome (ACS). In the treatment of CAD, reperfusion via percutaneous coronary intervention (PCI) combined with the placement of drug-eluting stents (DES) and fibrinolytics has considerably improved patient clinical results.1,2 Even while it significantly lessens post-infar
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits